Leniency PLUS+
The Leniency PLUS+
concept of
CDC is addressed to cartel members interested
in limiting the risk of being exposed to private damage claims by
cooperating
with CDC.
CDC shares the position of the European Commission and national
competition authorities that the public and private enforcement of
antitrust law complement each other. Leniency programmes play an
important role in the enforcement of antitrust law, because they
facilitate the uncovering of secret cartels. Former cartel members
willing to cooperate can provide relevant insights into the structure,
organisation and operation of cartels, and might provide information on
price effects on the markets concerned. With its
Leniency PLUS+
concept CDC extends the idea of public leniency programmes to the area
of private antitrust enforcement. It creates a further
incentive for cartel members
to limit the consequences of their past participation in illegal
cartels, because the Leniency PLUS
+ concept
reduces their risk exposure
to claims for damages resulting from anticompetitive practices.
-
Public
leniency programmes
-
The CDC Leniency PLUS+
concept
-
Frequently asked questions
Public
leniency programmes
Leniency programmes in the field of antitrust law respond to the fact
that cartels, by their very nature, are secret and usually difficult to
detect. It is widely acknowledged that
it
is in the public interest to grant undertakings involved in such
anticompetitive practices a benefit for successfully cooperating with
competition authorities in the investigation of the cartel.
Thus, cartel members which fulfil the conditions of public leniency
programmes may have their fine reduced substantially or they may be
able to avoid a penalty altogether. In some European countries (for
example,
England and Wales) individuals may also be able to avoid criminal
prosecution.
In order to benefit from public leniency programmes, the leniency
applicant has to cooperate with the competition authority during the
entire proceedings without cease and restriction. The leniency
applicants generally provide a corporate statement containing a
detailed description of the alleged antitrust law infringement, such as
information on the cartel participants, their meetings, the operation
of the cartel, the market concerned, the duration of the cartel and the
affected market volumes. In particular, leniency applicants normally
have to identify all undertakings and individuals involved in the
alleged cartel. Finally, upon request of the competition authorities,
they have to provide explanations in respect of the evidence submitted.
However, leniency applicants still face the risk of private actions for
damages resulting from a given cartel. In particular, leniency
applicants may be held liable for the entire damage caused by the
cartel, as the cartel members are jointly and severally liable in this
respect. An immunity or reduction of fines granted under public
leniency programmes does
not
protect cartel members from private damage actions
[see, for example, the 2006 Leniency Notice of the European Commission,
OJ C 298/17, 08/12/2006, para 39]. On the contrary, the information
submitted by leniency applicants to the competition authorities might
indirectly facilitate the substantiation of damage claims by cartel
victims.
In the antitrust damage cases that CDC has brought to court already,
that is, in the
German
Cement Cartel case and the
Bleaching Agent
Cartel case, some companies have previously cooperated under
the public
leniency programmes. Leniency programmes are also relevant in most of
the
other cases where
cartel activities have become publicly known and
therefore may be the basis of private damage claims.
Exemplary Leniency
Programmes in the EU:
•
European
Union
•
Germany
•
United
Kingdom
•
France
The
CDC Leniency PLUS+ Concept
The Leniency PLUS
+ concept of CDC is addressed
to
cartel members
interested in
actively managing their risk exposure in view of private damage actions.
The benefit resulting from the Leniency PLUS
+
concept might be taken
without, parallel, or subsequently to the participation in public
leniency programmes. CDC therefore also welcomes cartel members that
have not, or not successfully, participated in the public leniency
programme offered by the competition authorities.
The basic idea of Leniency PLUS
+ is to provide
incentives for cartel members to
cooperate in the private enforcement of antitrust law
by minimising their risks under the principle of joint and several
liability (see
Joint
and Several Liability).
An essential aspect under Leniency PLUS
+ is the
commitment of CDC not
to enforce damage claims against cooperating cartel members. The damage
action will only be enforced against the other cartel members. As CDC
is purchasing cartel-related damage claims from a multitude of damaged
companies, as well as from customers of other cartel members, CDC is in
position to bundle a large part of the damage claims to which Leniency
PLUS
+ candidates could potentially be exposed.
Therefore, cartel
members could even benefit twice if they decide to cooperate
under both the public leniency programmes and the CDC Leniency PLUS
+
concept. This double benefit strengthens the effectiveness of the
competition rules, while taking into account both the
victims’
fundamental right to full compensation for any loss caused by the
cartel and the interests of cartel members in a reasonable liquidation
of the legal consequences which they have to bear because of their
antitrust law infringement.
Thus, with its Leniency PLUS
+ concept CDC
contributes to a
reconciliation
of public leniency
programmes and the private enforcement of antitrust law.
CDC seeks to successfully enforce cartel-related damage claims without
preventing cartel members from benefiting from public leniency
programmes
and exposing public leniency applicants to an enlarged risk in
follow-on damage actions. The Leniency PLUS
+
concept responds to the
fact that the leniency programmes of the Commission and national
competition authorities do not oblige leniency applicants to compensate
for damages caused by the cartel.
In view of ensuring
confidentiality, details on the Leniency PLUS+
concept can be discussed
directly with CDC. If you are interested in this concept,
please
contact
CDC. You
can also send an email to:
LeniencyPLUS+@carteldamageclaims.com.
If you desire anonymity, please access a secure area
here.
For details on the login, please read the following information.
Frequently
asked questions
-
How can I contact
CDC anonymously?
-
How does CDC ensure
my anonymity?
-
How does CDC
ensure that no third party has access to my data or information?
How can I
contact CDC anonymously?
If you would like to contact CDC anonymously, you can access a
secure
area
and generate a username and a password of choice. In this way you can
communicate with CDC via an SSL- encoded connection which ensures a
high
degree of security and anonymity.
After having uploaded your username and password, your access will
automatically be activated. You can use your login data to log into the
CDC website and communicate with us in a protected area.
How does CDC ensure my
anonymity?
The username and password of choice will be the only two
elements CDC will be aware of. Please choose a username without
referring to your person or company. Uploaded login data will not
reveal any information. CDC will neither take note of your identity nor
be able to locate from where you communicate.
It is up to you to decide whether and when to contact CDC. Our response
will appear in the same text frame you created with your message. Thus,
we can communicate without being aware of your name, email-address or
any other detail relating to your identity.
How
does CDC ensure that no third party has access to my data or
information?
The SSL-encoded connection ensures that no third party can intercept
your user name and password. You will communicate with CDC only via our
secure server.
SSL means ‘Secure Socket Layer’. SSL provides for
encoded
data transfer between your internet browser and our server. It has
become a standard for encoding browser connections. Thus, all the data
you send to CDC cannot be read or manipulated by third parties. The
authenticity of the server is verified as well.
Printer
friendly version of this page 
CDC · Avenue Louise 475 · B-1050 Brussels · Tel: +32 (0) 2 213 49 20